9 documents found, page 1 of 1
Regulatory approval of photoimmunotherapy: photodynamic therapy that induces im...
Silva, Lígia C. Gomes da; Kepp, Oliver; Kroemer, GuidoIn September 2020, the Japanese government approved cetuximab saratolacan (previously known as RM-1929, commercial name: Akalux) for the treatment of unresectable locally advanced or recurrent head and neck cancer. Cetuximab saratolacan is a chemical conjugate of the photosensitizer IR700 with cetuximab, which targets EGFR. The treatment consists in the intravenous injection of cetuximab saratolacan, which bind...
Squaramide-based synthetic chloride transporters activate TFEB but block autoph...
Zhang, Shaoyi; Wang, Yan; Xie, Wei; Howe, Ethan N W; Busschaert, Nathalie; Sauvat, Allan; Leduc, Marion; Silva, Lígia C. Gomes da; Chen, GuoCystic fibrosis is a disease caused by defective function of a chloride channel coupled to a blockade of autophagic flux. It has been proposed to use synthetic chloride transporters as pharmacological agents to compensate insufficient chloride fluxes. Here, we report that such chloride anionophores block autophagic flux in spite of the fact that they activate the pro-autophagic transcription factor EB (TFEB) co...
Author Correction: Squaramide-based synthetic chloride transporters activate TF...
Zhang, Shaoyi; Wang, Yan; Xie, Wei; Howe, Ethan N W; Busschaert, Nathalie; Sauvat, Allan; Leduc, Marion; Silva, Lígia C. Gomes da; Chen, GuoIn the version of this article originally submitted, it was stated that the first three authors (Shaoyi_ Than, Yan Wang, Wei Xie) had contributed equally. However, in the published version this information was missing.
Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals
Zhou, Heng; Mondragón, Laura; Xie, Wei; Mauseth, Brynjar; Leduc, Marion; Sauvat, Allan; Silva, Lígia C. Gomes da; Forveille, SabrinaOncolytic peptides and peptidomimetics are being optimized for the treatment of cancer by selecting agents with high cytotoxic potential to kill a maximum of tumor cells as well as the capacity to trigger anticancer immune responses and hence to achieve long-term effects beyond therapeutic discontinuation. Here, we report on the characterization of two novel oncolytic peptides, DTT-205 and DTT-304 that both sel...
Guidelines and recommendations on yeast cell death nomenclature
Carmona-Gutierrez, Didac; Bauer, Maria Anna; Zimmermann, Andreas; Aguilera, Andrés; Austriaco, Nicanor; Ayscough, Kathryn; Balzan, RenaElucidating the biology of yeast in its full complexity has major implications for science, medicine and industry. One of the most critical processes determining yeast life and physiology is cel-lular demise. However, the investigation of yeast cell death is a relatively young field, and a widely accepted set of concepts and terms is still missing. Here, we propose unified criteria for the defi-nition of accide...
Combinatorial strategies for the induction of immunogenic cell death
Bezu, Lucillia; Silva, Lígia C. Gomes da; Dewitte, Heleen; Breckpot, Karine; Fucikova, Jitka; Spisek, Radek; Galluzzi, Lorenzo; Kepp, OliverThe term "immunogenic cell death" (ICD) is commonly employed to indicate a peculiar instance of regulated cell death (RCD) that engages the adaptive arm of the immune system. The inoculation of cancer cells undergoing ICD into immunocompetent animals elicits a specific immune response associated with the establishment of immunological memory. Only a few agents are intrinsically endowed with the ability to trigg...
Corrigendum: "Combinatorial Strategies for the Induction of Immunogenic Cell De...
Bezu, Lucillia; Silva, Lígia C. Gomes da; Dewitte, Heleen; Breckpot, Karine; Fucikova, Jitka; Spisek, Radek; Galluzzi, Lorenzo; Kepp, Oliver[This corrects the article on p. 187 in vol. 6, PMID: 25964783.].
Classification of current anticancer immunotherapies
Galluzzi, Lorenzo; Vacchelli, Erika; Bravo-San Pedro, José-Manuel; Buqué, Aitziber; Senovilla, Laura; Baracco, Elisa Elena; Bloy, NormaDuring the past decades, anticancer immunotherapy has evolved from a promising therapeutic option to a robust clinical reality. Many immunotherapeutic regimens are now approved by the US Food and Drug Administration and the European Medicines Agency for use in cancer patients, and many others are being investigated as standalone therapeutic interventions or combined with conventional treatments in clinical stud...
An AIF orthologue regulates apoptosis in yeast
Wissing, Silke; Ludovico, Paula; Herker, Eva; Buttner, Sabrina; Engelhardt, Silvia; Decker, Thorsten; Link, Alexander; Proksch, AstridApoptosis-inducing factor (AIF), a key regulator of cell death, is essential for normal mammalian development and participates in pathological apoptosis. The proapoptotic nature of AIF and its mode of action are controversial. Here, we show that the yeast AIF homologue Ynr074cp controls yeast apoptosis. Similar to mammalian AIF, Ynr074cp is located in mitochondria and translocates to the nucleus of yeast cells ...